Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, ≥99% Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at 2-8°C,Protected from light Ships Wet ice Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 24 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.
Irinotecan hydrochloride has been used:
in combination with 5-fluorouracil for screening growth inhibitory functionality in MDA-MB-231 breast cancer cells.
in chemosensitivity screening of high-grade appendiceal (HGA) and low-grade appendiceal (LGA) organoids.
as a chemotherapeutic agent in the cytotoxicity studies in combination with heat shock proteins inhibitors (HPSC1) in HT29 colon cancer cells.
| Pubchem Sid | 504753721 |
|---|---|
| Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/504753721 |
| Canonical Smiles | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7 |
| IUPAC Name | [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate |
| InChIKey | UWKQSNNFCGGAFS-XIFFEERXSA-N |
| INCHI | 1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1 |
| Isomeric SMILES | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7 |
| Molecular Weight | 586.68 |
| Reaxy-Rn | 4285693 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=4285693&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Alkaloids and derivatives |
| Class | Camptothecins |
| Subclass | Not available |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Camptothecins |
| Alternative Parents | Quinolines and derivatives Pyranopyridines Piperidinecarboxylic acids Aminopiperidines Pyridinones Benzenoids Tertiary alcohols Carbamate esters Heteroaromatic compounds Trialkylamines Carboxylic acid esters Lactams Lactones Organic carbonic acids and derivatives Azacyclic compounds Oxacyclic compounds Monocarboxylic acids and derivatives Organic oxides Hydrocarbon derivatives Organopnictogen compounds Carbonyl compounds |
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Camptothecin - Pyranopyridine - Quinoline - Piperidinecarboxylic acid - 4-aminopiperidine - Pyridinone - Piperidine - Pyridine - Benzenoid - Carbamic acid ester - Tertiary alcohol - Heteroaromatic compound - Amino acid or derivatives - Tertiary aliphatic amine - Tertiary amine - Carboxylic acid ester - Lactam - Lactone - Carbonic acid derivative - Oxacycle - Azacycle - Organoheterocyclic compound - Carboxylic acid derivative - Monocarboxylic acid or derivatives - Hydrocarbon derivative - Organonitrogen compound - Organooxygen compound - Organopnictogen compound - Alcohol - Carbonyl group - Organic oxygen compound - Organic nitrogen compound - Organic oxide - Amine - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring). |
| External Descriptors | Quinoline alkaloids |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Apr 07, 2026 | I127961 | |
| Certificate of Analysis | Feb 04, 2026 | I127961 | |
| Certificate of Analysis | Feb 04, 2026 | I127961 | |
| Certificate of Analysis | Nov 13, 2025 | I127961 | |
| Certificate of Analysis | Nov 13, 2025 | I127961 | |
| Certificate of Analysis | Nov 13, 2025 | I127961 | |
| Certificate of Analysis | Mar 24, 2025 | I127961 | |
| Certificate of Analysis | Mar 24, 2025 | I127961 | |
| Certificate of Analysis | Mar 24, 2025 | I127961 | |
| Certificate of Analysis | Jun 25, 2024 | I127961 | |
| Certificate of Analysis | Jun 25, 2024 | I127961 | |
| Certificate of Analysis | Jun 13, 2023 | I127961 | |
| Certificate of Analysis | Jun 13, 2023 | I127961 | |
| Certificate of Analysis | Jun 11, 2022 | I127961 |
| Solubility | Soluble in DMSO (10 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C). |
|---|---|
| Sensitivity | Light sensitive |
| Molecular Weight | 586.700 g/mol |
| XLogP3 | 3.000 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 586.279 Da |
| Monoisotopic Mass | 586.279 Da |
| Topological Polar Surface Area | 113.000 Ų |
| Heavy Atom Count | 43 |
| Formal Charge | 0 |
| Complexity | 1200.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |
| 1. Yifan Wu, Xiaoxia Gong, Jianzhong Shen, Kui Zhu. (2023) Postantibiotic leukocyte enhancement-mediated reduction of intracellular bacteria by macrophages. Journal of Advanced Research, [PMID:37290606] [10.1016/j.jare.2023.05.010] |
| 2. Zhongcheng Yang, Zhijun Cao, Wenxin Wang, Ya Chen, Wanqiu Huang, Shixuan Jiao, Siliang Chen, Lianru Chen, Yuxia Liu, Jianming Mao, Luyong Zhang, Zheng Li. (2023) Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea. BIOORGANIC CHEMISTRY, [PMID:37300962] [10.1016/j.bioorg.2023.106625] |
| 3. Lanhong Su, Wen Pan, Xiangxia Li, Xingyu Zhou, Xiaopeng Ma, Yuanzeng Min. (2022) Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy. Acta Biomaterialia, [PMID:36563773] [10.1016/j.actbio.2022.12.039] |
| 4. Lanhong Su, Yuhao Hao, Rui Li, Wen Pan, Xiaopeng Ma, Jianping Weng, Yuanzeng Min. (2022) Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy. Acta Biomaterialia, [PMID:36241013] [10.1016/j.actbio.2022.10.001] |
| 5. Bo Lv, Ruijie Xu, Xinrui Xing, Chuyao Liao, Zunjian Zhang, Pei Zhang, Fengguo Xu. (2022) Discovery of Synergistic Drug Combinations for Colorectal Cancer Driven by Tumor Barcode Derived from Metabolomics “Big Data”. Metabolites, 12 (6): (494). [PMID:35736427] [10.3390/metabo12060494] |
| 6. Jiao Yang Lu, Fu Rui Zhang, Xue Zhi Ding, Li Qiu Xia, Wei Tao Huang. (2021) Natural interface guiding cell: Directly using waste fish scales with rich micro/nano structures for control of cell behaviors. APPLIED SURFACE SCIENCE, [PMID:] [10.1016/j.apsusc.2021.152348] |
| 7. Yue Shi-Jun, Qin Yi-Feng, Kang An, Tao Hui-Juan, Zhou Gui-Sheng, Chen Yan-Yan, Jiang Jian-Qin, Tang Yu-Ping, Duan Jin-Ao. (2021) Total Flavonoids of Glycyrrhiza uralensis Alleviates Irinotecan-Induced Colitis via Modification of Gut Microbiota and Fecal Metabolism. Frontiers in Immunology, [PMID:34025639] [10.3389/fimmu.2021.628358] |
| 8. Dou-Dou XU, Xiao-Ying HOU, Ou WANG, Di WANG, Dan-Ting LI, Si-Yuan QIN, Bo LV, Xiao-Min DAI, Zun-Jian ZHANG, Jian-Bo WAN, Feng-Guo XU. (2021) A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan. Chinese Journal of Natural Medicines, [PMID:33941341] [10.1016/S1875-5364(21)60034-1] |
| 9. Ling Duan, Leijiao Deng, Dabin Wang, Shoucheng Ma, Chunmei Li, Da Zhao. (2017) Treatment mechanism of matrine in combination with irinotecan for colon cancer. Oncology Letters, 14 (2): (2300-2304). [PMID:28781667] [10.3892/ol.2017.6407] |
| 10. Zhou Hongyan, Hu Dingxin, Zhao Xian, Qin Siyuan, Nong Qiyao, Tian Yuan, Zhang Zunjian, Dong Haijuan, Zhang Pei, Xu Fengguo. (2024) An optimal combination of four active components in Huangqin decoction for the synergistic sensitization of irinotecan against colorectal cancer. Chinese Medicine, 19 (1): (1-12). [PMID:38956673] [10.1186/s13020-024-00967-1] |
| 11. Miaomiao Sun, Honghong Zhan, Xiaoliang Long, Ali M. Alsayed, Zhe Wang, Fancheng Meng, Guowei Wang, Jingxin Mao, Zhihua Liao, Min Chen. (2024) Dehydrocostus lactone alleviates irinotecan-induced intestinal mucositis by blocking TLR4/MD2 complex formation. PHYTOMEDICINE, [PMID:38518649] [10.1016/j.phymed.2024.155371] |
| 12. Ya-Kun Zhang, Jian-Bo Tong, Hong-Yan Zhang, Mu-Xuan Luo, Zhi-Peng Qing, Cheng-Jian Tan. (2025) Design, synthesis, and antitumor evaluation of sophoridine derivatives as topoisomerase I inhibitors based on the topomer CoMFA model. JOURNAL OF MOLECULAR STRUCTURE, [PMID:] [10.1016/j.molstruc.2025.142005] |
| 13. Yukun Zhong, Haining Li, Teng Jiang, Xueliang Mu, Munetoshi Seki, U Kei Cheang. (2024) Double-Layered Metal-Organic-Frameworks-Based Microswimmers for Adaptive Dual-Drug Anti-Cancer Therapy Using Artemisinin-Based Compounds. Advanced Intelligent Systems, [PMID:] [10.1002/aisy.202400244] |
| 14. Yuan-yuan Zhai, Qiang Wang, Qi-yao Nong, Mei-yu Gao, Ying Zhang, Qin-wen Xiao, Yuan Tian, Zun-jian Zhang, Feng-guo Xu, Pei Zhang. (2025) Pitavastatin overcomes multi-drug resistance in CRC and NSCLC by targeting the NRP1-ZFX axis. BIOCHEMICAL PHARMACOLOGY, [PMID:40684995] [10.1016/j.bcp.2025.117183] |
| 15. Lumei Dai, Shifang Wen, Yaling Chen, Xinchun Li, Bing Zhao, Xinyu You, Rongqiang Li, Bin Zhang. (2025) Self-assembled dual-target ibuprofen-irinotecan conjugate for colorectal cancer therapy. BIOORGANIC & MEDICINAL CHEMISTRY, [PMID:40850193] [10.1016/j.bmc.2025.118367] |
| 16. Yaowei Guo, Jin Liu, Qinglin Tang, Cuicui Li, Yanying Zhang, Yao Wang, Yanxin Wang, Yupeng Bi, Christopher D. Snow, Matt J. Kipper, Laurence A. Belfiore, Jianguo Tang. (2022) Lanthanide (Eu3+/Tb3+)-Loaded γ-Cyclodextrin Nano-Aggregates for Smart Sensing of the Anticancer Drug Irinotecan. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23 (12): (6597). [PMID:35743042] [10.3390/ijms23126597] |
| 17. Mengjing Zhao, Tianpeng Zhang, Fangjun Yu, Lianxia Guo, Baojian Wu. (2018) E4bp4 regulates carboxylesterase 2 enzymes through repression of the nuclear receptor Rev-erbα in mice. BIOCHEMICAL PHARMACOLOGY, [PMID:29653076] [10.1016/j.bcp.2018.04.005] |
| 18. Zhao Xian, Xu Ruijie, Zhai Yuanyuan, Wang Yi, Zhang Yuxin, Tian Yuan, Xu Fengguo, Zhang Pei. (2025) Liposomal Vardenafil and Linagliptin Combined with Irinotecan for Synergistic Colorectal Cancer Therapy. PHARMACEUTICAL RESEARCH, [PMID:40473893] [10.1007/s11095-025-03876-6] |
| 19. Shuiling Jin, Aifang Zhou, Qi Zhang, Di Zhao, Xintong Dong, Hong-Min Meng, Zhengquan Yu, Zhaohui Li. (2025) Engineered Cancer Cell Membrane-Functionalized Metal-Organic Frameworks for Irinotecan/Curcumin Codelivery in Colorectal Cancer: Enhanced Efficacy and Mitigated Toxicity. International Journal of Nanomedicine, [PMID:41287765] [10.2147/IJN.S558675] |
| 20. Jiang Huan-guo, Zhan Zhi-kun, Tian Ling-min, Chen Yu-lian, Cai Mei-qun, Ge Guang-bo, Chen Xin, Wei Chuan-liang, Tang Lan. (2026) Oridonin exerts dual therapeutic effects in MASLD mice by integrating lipid homeostasis and drug bioactivation via the LXRα–CES1/CES2 pathway. ACTA PHARMACOLOGICA SINICA, [PMID:41639319] [10.1038/s41401-025-01737-x] |
| 21. Yunhan Wang, Xinming Zhang, Fang Fang, Yunyan Chen, Yu Sun. (2026) NIR-activatable and colorectal cancer-targeted lipid polymer hybrid nanoparticles: Design and in vivo assessment. JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY, [PMID:] [10.1080/01932691.2026.2625044] |
| 22. Yuanyuan Zhang, Mingyang Liu, Yifan Zhang, Fengxia Qin, Yuan Tian, Fengguo Xu, Yuxin Zhang, Pei Zhang. (2026) Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts. BIOCHEMICAL PHARMACOLOGY, [PMID:] [10.1016/j.bcp.2026.117904] |
| 23. Nishtha Thakur, Pablo Mota-Santiago, Shuddhodana, Zaher Judeh. (2026) Interfacial Modulation of Cochleate Assembly via Cationic Surfactant Enables Enhanced Encapsulation of Water-Soluble Drugs. COLLOIDS AND SURFACES B-BIOINTERFACES, [PMID:] [10.1016/j.colsurfb.2026.115601] |
| 24. Mengxi Xiang, Cheng Zhou, Chundong Yao, Jia Liu, Lin Wang, Zheng Wang. (2026) A Self-Assembled Irinotecan Nanomedicine Abrogates Steatohepatitis-Induced Liver Metastasis and Potentiates Antitumor Efficacy against Colorectal Cancer. ACS Nano, [PMID:] [10.1021/acsnano.6c00855] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →